Harvard Pilgrim Health Care, which has offices in Worcester and is based in Cambridge, has signed two outcomes-based contracts with Great Britain drug developer AstraZeneca for medicines that treat acute coronary disease and Type 2 Diabetes.
The outcomes-based system means that Harvard Pilgrim will be charged based on value to the patient, not just on volume of medicine sold, according to a release from the company.
The first contract is for Brilinta, which is used to lower a patient’s chances of having another heart attack, or dying from one. The second is for Bydureon, which controls blood glucose levels in patients with Type 2 Diabetes.
If the medicines don’t meet the agreed upon outcomes criteria in patients, Harvard Pilgrim will be charged a lower amount.
The two contracts are the latest in a series of outcome-based agreements Harvard Pilgrim has entered into to measure the effectiveness of medicines.
